Second Quarter Net Income Increased 79%
Second Quarter Sales Increased 10%
Second Quarter Online Sales Increased 12%
DELRAY BEACH, Fla., Oct. 23, 2017 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ:PETS) today announced its financial results for the quarter ended September 30, 2017. Net income was $8.8 million, or $0.43 diluted per share, for the quarter ended September 30, 2017, compared to net income of $4.9 million, or $0.24 diluted per share, for the quarter ended September 30, 2016, a 79% increase to net income. Net income for the six months ended September 30, 2017 was $18.0 million, or $0.88 diluted per share, compared to net income of $11.5 million, or $0.56 diluted per share, for the six months ended September 30, 2016, a 57% increase to net income. Net sales for the quarter ended September 30, 2017 were $66.7 million, compared to $60.8 million for the quarter ended September 30, 2016, an increase of 10%. Net sales for the six months ended September 30, 2017 were $146.4 million, compared to $133.3 million for the six months ended September 30, 2016, an increase of 10%. New order sales increased 9%, to $11.6 million for the quarter ended September 30, 2017, compared to $10.7 million for the same quarter in the prior year. The Company’s online sales for the quarter ended September 30, 2017 were approximately 84% of all sales compared to 82% for the same quarter the prior year, with online sales increasing 12%.
Menderes Akdag, CEO and President, commented: “The trend we have seen in the last two quarters continued with increases in both new order and reorder sales during the quarter, along with an accelerated increase to net income for the third consecutive quarter. This increase to net income can be attributed to increased revenue with a shift in sales to higher margin items in the flea, tick and heartworm categories. Gross profit as a percentage of sales increased to 35.2% for the quarter ended September 30, 2017, compared to 29.7% for the quarter ended September 30, 2016. Also, an income tax benefit of approximately $807,000 related to stock-based compensation was recognized in the quarter ended September 30, 2017. Average order value increased to $85 for the quarter compared to $82 for the same quarter the prior year. For the remainder of fiscal 2018 we will continue to focus on increasing sales and improving our service levels.”
The Board of Directors declared a quarterly dividend of $0.20 per share on the Company’s common stock. The dividend will be payable on November 17, 2017, to shareholders of record at the close of business on November 6, 2017. The Company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance.
This morning at 8:30 A.M. Eastern Time, Mr. Akdag will host a conference call to review the quarter’s financial results. To access the call, which is open to the public, please dial (888) 455-1758 (toll free) or (203) 827-7025. Callers will be required to supply PETMEDS as the passcode. For those unable to participate in the live event, the call will be available for replay from 10:00 A.M. on October 23, 2017 until November 6, 2017 at 10:59 P.M. To access the replay, call (800) 839-2239 (toll free) or (203) 369-3108, and enter passcode 5500.
Founded in 1996, PetMed Express is America’s Largest Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs and cats at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com.
This press release may contain “forward-looking” statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such “forward-looking” statements are set forth in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2017. The Company’s future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K. For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 561-526-4444.
| PETMED EXPRESS, INC. AND SUBSIDIARIES | ||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||
| (In thousands) | ||||
| September 30, | March 31, | |||
| 2017 | 2017 | |||
| ASSETS | (Unaudited) | |||
| Current assets: | ||||
| Cash and cash equivalents | $ | 68,443 | $ | 58,730 |
| Accounts receivable, less allowance for doubtful | ||||
| accounts of $31 and $27, respectively | 2,012 | 1,808 | ||
| Inventories - finished goods | 23,005 | 20,228 | ||
| Prepaid expenses and other current assets | 1,106 | 1,019 | ||
| Total current assets | 94,566 | 81,785 | ||
| Noncurrent assets: | ||||
| Property and equipment, net | 29,456 | 30,164 | ||
| Intangible assets | 860 | 860 | ||
| Total noncurrent assets | 30,316 | 31,024 | ||
| Total assets | $ | 124,882 | $ | 112,809 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||
| Current liabilities: | ||||
| Accounts payable | $ | 10,376 | $ | 15,221 |
| Accrued expenses and other current liabilities | 2,871 | 2,475 | ||
| Income taxes payable | 6,008 | 659 | ||
| Total current liabilities | 19,255 | 18,355 | ||
| Deferred tax liabilities | 1,304 | 1,088 | ||
| Total liabilities | 20,559 | 19,443 | ||
| Commitments and contingencies | ||||
| Shareholders' equity: | ||||
| Preferred stock, $.001 par value, 5,000 shares authorized; | ||||
| 3 convertible shares issued and outstanding with a | ||||
| liquidation preference of $4 per share | 9 | 9 | ||
| Common stock, $.001 par value, 40,000 shares authorized; | ||||
| 20,604 and 20,526 shares issued and outstanding, respectively | 21 | 21 | ||
| Additional paid-in capital | 7,952 | 6,806 | ||
| Retained earnings | 96,341 | 86,530 | ||
| Total shareholders' equity | 104,323 | 93,366 | ||
| Total liabilities and shareholders' equity | $ | 124,882 | $ | 112,809 |
| PETMED EXPRESS, INC. AND SUBSIDIARIES | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | ||||||||
| (In thousands, except for per share amounts) (Unaudited) | ||||||||
| Three Months Ended | Six Months Ended | |||||||
| September 30, | September 30, | |||||||
| 2017 | 2016 | 2017 | 2016 | |||||
| Sales | $ | 66,711 | $ | 60,791 | $ | 146,368 | $ | 133,278 |
| Cost of sales | 43,232 | 42,727 | 95,424 | 92,762 | ||||
| Gross profit | 23,479 | 18,064 | 50,944 | 40,516 | ||||
| Operating expenses: | ||||||||
| General and administrative | 6,178 | 5,747 | 12,404 | 11,845 | ||||
| Advertising | 4,526 | 4,382 | 10,818 | 10,142 | ||||
| Depreciation | 527 | 204 | 1,058 | 398 | ||||
| Total operating expenses | 11,231 | 10,333 | 24,280 | 22,385 | ||||
| Income from operations | 12,248 | 7,731 | 26,664 | 18,131 | ||||
| Other income: | ||||||||
| Interest income, net | 143 | 32 | 226 | 60 | ||||
| Other, net | 249 | 23 | 490 | 76 | ||||
| Total other income | 392 | 55 | 716 | 136 | ||||
| Income before provision for income taxes | 12,640 | 7,786 | 27,380 | 18,267 | ||||
| Provision for income taxes | 3,880 | 2,887 | 9,344 | 6,774 | ||||
| Net income | $ | 8,760 | $ | 4,899 | $ | 18,036 | $ | 11,493 |
| Comprehensive income | $ | 8,760 | $ | 4,899 | $ | 18,036 | $ | 11,493 |
| Net income per common share: | ||||||||
| Basic | $ | 0.43 | $ | 0.24 | $ | 0.89 | $ | 0.57 |
| Diluted | $ | 0.43 | $ | 0.24 | $ | 0.88 | $ | 0.56 |
| Weighted average number of common shares outstanding: | ||||||||
| Basic | 20,349 | 20,234 | 20,321 | 20,208 | ||||
| Diluted | 20,437 | 20,377 | 20,442 | 20,355 | ||||
| Cash dividends declared per common share | $ | 0.20 | $ | 0.19 | $ | 0.40 | $ | 0.38 |
| PETMED EXPRESS, INC. AND SUBSIDIARIES | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| (In thousands) (Unaudited) | |||||||
| Six Months Ended | |||||||
| September 30, | |||||||
| 2017 | 2016 | ||||||
| Cash flows from operating activities: | |||||||
| Net income | $ | 18,036 | $ | 11,493 | |||
| Adjustments to reconcile net income to net cash | |||||||
| provided by operating activities: | |||||||
| Depreciation | 1,058 | 398 | |||||
| Share based compensation | 1,146 | 946 | |||||
| Deferred income taxes | 216 | 364 | |||||
| Bad debt expense | 46 | 352 | |||||
| (Increase) decrease in operating assets | |||||||
| and increase (decrease) in liabilities: | |||||||
| Accounts receivable | (250 | ) | 3 | ||||
| Inventories - finished goods | (2,777 | ) | 10,765 | ||||
| Prepaid income taxes | - | 222 | |||||
| Prepaid expenses and other current assets | (87 | ) | 1,764 | ||||
| Accounts payable | (4,845 | ) | 1,143 | ||||
| Income taxes payable | 5,349 | - | |||||
| Accrued expenses and other current liabilities | 411 | 335 | |||||
| Net cash provided by operating activities | 18,303 | 27,785 | |||||
| Cash flows from investing activities: | |||||||
| Purchases of property and equipment | (350 | ) | (5,859 | ) | |||
| Net cash used in investing activities | (350 | ) | (5,859 | ) | |||
| Cash flows from financing activities: | |||||||
| Dividends paid | (8,240 | ) | (7,784 | ) | |||
| Excess tax benefits related to restricted stock | - | 115 | |||||
| Net cash used in financing activities | (8,240 | ) | (7,669 | ) | |||
| Net increase in cash and cash equivalents | 9,713 | 14,257 | |||||
| Cash and cash equivalents, at beginning of period | 58,730 | 37,639 | |||||
| Cash and cash equivalents, at end of period | $ | 68,443 | $ | 51,896 | |||
| Supplemental disclosure of cash flow information: | |||||||
| Cash paid for income taxes | $ | 3,780 | $ | 6,186 | |||
| Prepaid property and equipment in current assets | $ | - | $ | 5,815 | |||
| Dividends payable in accrued expenses | $ | 202 | $ | 144 | |||